Investment Rating - The report upgrades the investment rating of the company to "Buy" [10] Core Views - The IND application for BGM0504 has been accepted, marking a significant step for the company as it prepares to enter clinical trials with a rare dual-target oral peptide [9] - The potential of amylin is highlighted, with BGM1812 being a long-acting amylin analog currently in the preclinical stage, indicating a favorable competitive landscape [3] - The oral formulation of BGM0504 is expected to have better compliance and penetration compared to injectable forms, with the same molecular structure showing promising efficacy in previous studies [9] Financial Projections - The company forecasts total revenue of 1,180 million in 2023, increasing to 1,762 million by 2027, reflecting a compound annual growth rate (CAGR) of 18.21% [11] - The projected net profit attributable to the parent company is expected to rise from 202.47 million in 2023 to 433.39 million in 2027, with a notable growth rate of 43.06% in 2027 [11] - The earnings per share (EPS) is projected to increase from 0.48 in 2023 to 1.03 in 2027, indicating a strong upward trend in profitability [11] Market Data - The closing price of the stock is reported at 69.16 yuan, with a market capitalization of approximately 29,238.65 million [6] - The price-to-earnings (P/E) ratio is currently at 144.41, expected to decrease to 67.47 by 2027, suggesting improving valuation metrics as earnings grow [11]